Houston superstar Simone Biles snags C-suite position in SoftBank-backed company

flipping into tech

Houston's favorite gymnast is the chief impact officer on a California-based tech company that's raised $462M. Photo via getcerebral.com

Less than two months after Olympic gymnastics star Simone Biles of Spring joined mental health startup Cerebral as chief impact officer, the company has raised $300 million in venture capital — a sum that vaulted it to a valuation of $4.8 billion.

San Francisco-based Cerebral announced the $300 million round December 8. SoftBank Vision Fund 2 led the Series C round, with participation from Prysm Capital, Access Industries, WestCap Group, and ARTIS Ventures.

Launched in January 2020, Cerebral has raised a total of $462 million from investors, including an undisclosed amount from Biles.

Biles, a 4-foot, 8-inch gymnastics powerhouse, has won 32 Olympic and World Championship medals. But it was her off-the-mat moves at this year’s Summer Olympics in Tokyo that drew worldwide attention. Biles contended in just one event in Tokyo after withdrawing from all other competition to concentrate on her mental health.

Two months after the Olympics, Biles agreed to become Cerebral’s chief impact officer, serving as the face of the brand.

Cerebral was an official sponsor of Biles’ Gold Over America Tour, which took place from September to November, and is an official sponsor of the 2022 Simone Biles International Invitational, a gymnastics competition that will be held January 27-30 at Houston’s George R. Brown Convention Center. The Spring-based World Champions Centre, Biles’ home gym, stages the invitational.

“Mental health is just as important as physical health, but for far too long the stigma of mental health has prevented too many people from seeking help,” Biles says in a Cerebral news release. “I have my own challenges with mental health, and therapy has been very empowering for me as I try to be the best person that I can be. I believe everyone should have access to mental health resources, and Cerebral gives me the ability to personalize my mental health care experience.”

Cerebral bills itself as a one-stop online shop for mental health care and wellness. The company offers counseling, therapy, and medication delivery and management online for conditions such as depression, anxiety, and substance abuse.

Cerebral boasts that the $300 million round makes it the world’s largest and fastest-growing online provider of mental health services.

“Cerebral’s growth in the last year shows just how much the world needs affordable and accessible mental health care. It’s important to us that we not only improve access to mental health care through a convenient platform and affordable plans, but to also improve patient outcomes,” says Kyle Robertson, co-founder and CEO of Cerebral.

The pandemic ramped up the use of telehealth services, including those delivered by Cerebral. According to Fortune Business Insights, the U.S. market for behavioral health grew 11.3 percent in 2020, with pandemic-fueled mental health concerns helping drive up demand. Fortune Business Insights estimates the U.S. market will expand from $77.62 billion in 2021 to $99.4 billion in 2028.

Globally, the mental health market is projected to jump from $383.31 billion in 2020 to $537.97 billion by 2030, according to Allied Market Research.

Digital health startups like Cerebral are benefiting from the mushrooming market for mental health. Rock Health, an investment and advisory firm, says that through the first nine months of 2021, investors pumped $21.3 billion into U.S. digital health startups. That compares with $14.6 billion in all of 2020.

Cerebral says its $300 million cash infusion will enable it to undertake a global expansion, as well develop strategic partnerships and explore M&A opportunities. Today, Cerebral comprises a network of over 2,300 clinicians practicing in all 50 states.

“Roughly half of the American population is affected by mental health issues. However, obstacles like cost, limited provider availability, and fear of judgment remain in the way of getting the treatment they need,” says Priya Saiprasad, a partner at SoftBank Investment Advisers, which manages SoftBank’s venture capital funds.

After relocating its headquarters to Houston, Katerra has filed for bankruptcy. Photo via Getty Images

New-to-Houston construction tech company files for Chapter 11 bankruptcy

bad news

Construction startup Katerra, which only recently moved its North American headquarters from Silicon Valley to Houston, filed for Chapter 11 bankruptcy June 6 — five days after news reports indicated the company was shutting down most of its U.S. operations.

Katerra's filings in U.S. Bankruptcy Court in Houston show the company and various affiliates have between $1 billion and $10 billion in liabilities and only $500 million to $1 billion in assets. In a June 6 news release, Katerra says it lined up $35 million in financing from a unit of Japan's SoftBank Group, the startup's largest investor.

Katerra recently notified its key stakeholders that many of its U.S. projects will be "demobilizing," according to the news release.

In an email sent June 1 to employees, Katerra said it would be winding down the majority of its U.S. operations and would lay off most of its U.S. employees. News website The Information first reported about the email. Globally, Katerra employs about 7,500 people.

Aside from letting go thousands of employees, Katerra is likely to walk away from dozens of construction projects it had agreed to build, The Information reported. As part of the bankruptcy case, Katerra plans to sell its renovation and Lord Aeck Sargent architecture businesses to unidentified buyers.

Katerra has been hemorrhaging money for months. In December, SoftBank pumped $200 million into Katerra, in addition to its previous investment of roughly $2 billion. Five months after Katerra received that cash infusion, Paal Kibsgaard stepped down as CEO, a role he'd held since July 2020. Kibsgaard is former chairman and CEO of Houston-based Schlumberger.

"The rapid deterioration of the company's financial position is the result of the macroeconomic effects of the COVID-19 pandemic on the construction industry, inability to procure bonding for construction projects following the unexpected insolvency proceedings of Katerra's former lender, and unsuccessful attempts to secure additional capital and business," according to the news release announcing the bankruptcy proceedings.

Greensill Capital, the lender referenced in the news release, filed for insolvency protection in March. Like Katerra, Greensill is backed by SoftBank.

Katerra was founded in 2015 with the intent to capitalize on technology — such as automation and robotics — in order to streamline construction. Its projects have included hotels and apartment buildings. Last year, it posted nearly $2 billion in revenue.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston engineers develop breakthrough device to advance spinal cord treatment

future of health

A team of Rice University engineers has developed an implantable probe over a hundred times smaller than the width of a hair that aims to help develop better treatments for spinal cord disease and injury.

Detailed in a recent study published in Cell Reports, the probe or sensor, known as spinalNET, is used to explore how neurons in the spinal cord process sensation and control movement, according to a statement from Rice. The research was supported by the National Institutes of Health, Rice, the California-based Salk Institute for Biological Studies, and the philanthropic Mary K. Chapman Foundation based in Oklahoma.

The soft and flexible sensor was used to record neuronal activity in freely moving mice with high resolution for multiple days. Historically, tracking this level of activity has been difficult for researchers because the spinal cord and its neurons move so much during normal activity, according to the team.

“We developed a tiny sensor, spinalNET, that records the electrical activity of spinal neurons as the subject performs normal activity without any restraint,” Yu Wu, a research scientist at Rice and lead author of the study said in a statement. “Being able to extract such knowledge is a first but important step to develop cures for millions of people suffering from spinal cord diseases.”

The team says that before now the spinal cord has been considered a "black box." But the device has already helped the team uncover new findings about the body's rhythmic motor patterns, which drive walking, breathing and chewing.

Lan Luan (from left), Yu Wu, and Chong Xie are working on the breakthrough device. Photo by Jeff Fitlow/Rice University

"Some (spinal neurons) are strongly correlated with leg movement, but surprisingly, a lot of neurons have no obvious correlation with movement,” Wu said in the statement. “This indicates that the spinal circuit controlling rhythmic movement is more complicated than we thought.”

The team said they hope to explore these findings further and aim to use the technology for additional medical purposes.

“In addition to scientific insight, we believe that as the technology evolves, it has great potential as a medical device for people with spinal cord neurological disorders and injury,” Lan Luan, an associate professor of electrical and computer engineering at Rice and a corresponding author on the study, added in the statement.

Rice researchers have developed several implantable, minimally invasive devices to address health and mental health issues.

In the spring, the university announced that the United States Department of Defense had awarded a four-year, $7.8 million grant to the Texas Heart Institute and a Rice team led by co-investigator Yaxin Wang to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation.

That same month, the university shared news that Professor Jacob Robinson had published findings on minimally invasive bioelectronics for treating psychiatric conditions. The 9-millimeter device can deliver precise and programmable stimulation to the brain to help treat depression, obsessive-compulsive disorder and post-traumatic stress disorder.

Houston clean hydrogen startup to pilot tech with O&G co.

stay gold

Gold H2, a Houston-based producer of clean hydrogen, is teaming up with a major U.S.-based oil and gas company as the first step in launching a 12-month series of pilot projects.

The tentative agreement with the unnamed oil and gas company kicks off the availability of the startup’s Black 2 Gold microbial technology. The technology underpins the startup’s biotech process for converting crude oil into proprietary Gold Hydrogen.

The cleantech startup plans to sign up several oil and gas companies for the pilot program. Gold H2 says it’s been in discussions with companies in North America, Latin America, India, Eastern Europe and the Middle East.

The pilot program is aimed at demonstrating how Gold H2’s technology can transform old oil wells into hydrogen-generating assets. Gold H2, a spinout of Houston-based biotech company Cemvita, says the technology is capable of producing hydrogen that’s cheaper and cleaner than ever before.

“This business model will reshape the traditional oil and gas industry landscape by further accelerating the clean energy transition and creating new economic opportunities in areas that were previously dismissed as unviable,” Gold H2 says in a news release.

The start of the Black 2 Gold demonstrations follows the recent hiring of oil and gas industry veteran Prabhdeep Singh Sekhon as CEO.

“With the proliferation of AI, growth of data centers, and a national boom in industrial manufacturing underway, affordable … carbon-free energy is more paramount than ever,” says Rayyan Islam, co-founder and general partner at venture capital firm 8090 Industries, an investor in Gold H2. “We’re investing in Gold H2, as we know they’ll play a pivotal role in unleashing a new dawn for energy abundance in partnership with the oil industry.”

------

This article originally ran on EnergyCapital.

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes an e-commerce startup founder, an industrial biologist, and a cellular scientist.

Omair Tariq, co-founder and CEO of Cart.com

Omair Tariq of Cart.com joins the Houston Innovators Podcast to share his confidence in Houston as the right place to scale his unicorn. Photo via Cart.com

Houston-based Cart.com, which operates a multichannel commerce platform, has secured $105 million in debt refinancing from investment manager BlackRock.

The debt refinancing follows a recent $25 million series C extension round, bringing Cart.com’s series C total to $85 million. The scaleup’s valuation now stands at $1.2 billion, making it one of the few $1 billion-plus “unicorns” in the Houston area.

Cart.com was co-founded by CEO Omair Tariq in October 2020. Read more.

Nádia Skorupa Parachin, vice president of industrial biotechnology at Cemvita

Nádia Skorupa Parachin joined Cemvita as vice president of industrial biotechnology. Photo courtesy of Cemvita

Houston-based biotech company Cemvita recently tapped two executives to help commercialize its sustainable fuel made from carbon waste.

Nádia Skorupa Parachin came aboard as vice president of industrial biotechnology, and Phil Garcia was promoted to vice president of commercialization.

Parachin most recently oversaw several projects at Boston-based biotech company Ginkjo Bioworks. She previously co-founded Brazilian biotech startup Integra Bioprocessos. Read more.

Han Xiao, associate professor of chemistry at Rice University

The funds were awarded to Han Xiao, a chemist at Rice University.

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories. Xiao will use the five-year grant to advance his work on noncanonical amino acids.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement. Read more.

View All Listings